Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Abstract

BackgroundRotavirus is the leading cause of severe gastroenteritis in children <5 years of age and is responsible for >500,000 deaths annually; ∼85% of this burden is in low-income countries eligible for financial support from the GAVI Alliance. We projected the uptake, health impact, and cost-effectiveness of introducing rotavirus vaccination in GAVI-eligible countries to help policy makers in prioritizing resources to gain the greatest health improvements for their constituencies

MethodsA demand forecast model was used to predict adoption of rotavirus vaccine in the poorest countries in the world. We then modeled health outcomes and direct costs of a hypothetical birth cohort in the target population for scenarios with and without a rotavirus vaccine with use of data on health outcomes of rotavirus infection, vaccine effectiveness, and immunization rates

ResultsVaccination would prevent 2.4 million rotavirus deaths and >82 million disability-adjusted life-years (DALYs) in 64 of the 72 GAVI-eligible countries introducing vaccine from 2007 through 2025. The cost per DALY averted decreases over time, from a high of US$450 per DALY averted in the first year to a sustained low of $30 per DALY during 2017–2025, with a cumulative figure of $43 per DALY averted during 2008–2025. By applying the baseline scenario with an initial vaccine price of $7 per dose for a 2-dose vaccine, with a gradual decrease beginning in 2012 and stabilizing at $1.25 per dose by 2017, vaccination was very cost-effective in all GAVI-eligible countries with use of each country’s gross domestic product per DALY averted as a threshold

ConclusionsIntroduction of rotavirus vaccines into the world’s poorest countries is very cost-effective and is projected to substantially reduce childhood mortality

© 2009 by the Infectious Diseases Society of America
Topic:
Issue Section:
Supplement Article
You do not currently have access to this article.
Download all slides